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Abstract
The eye is a delicate organ that, along with other tissues such as the testicles and 
brain, is considered immune-privileged. Immune cells that reside in the eye must 
create a tolerogenic microenvironment to prevent unwanted aggressive inflam-
matory reactions that can compromise function. However, the eye is exposed to 
persistent environmental insult that may overwhelm immune tolerance and result in 
eye diseases from diverse origins (autoimmune, infectious, and inflammatory). The 
immune system plays a central role in the different phases of eye diseases, as altera-
tions in immune cells in response to mechanical, chemical, or infectious stimuli 
initiate and amplify the immune response that lead to ocular tissue damage. Both 
resident and infiltrating immune cells also actively inhibit the immune response and 
promote tissue repair. Emerging evidence is leading to a better understanding of 
how and when lymphocytes, amongst other immune cells, contribute to inflamma-
tory diseases such as dry eye disease (DED). We have compiled literature identifying 
the presence and participation of lymphocyte subpopulations that modulate DED 
from studies in both mice and humans. Notably, most mouse studies have relied on 
desiccant-stress-induced models (non-autoimmune DED), whereas human studies 
are predominantly in patients with Sjögren’s syndrome (autoimmune DED).
Keywords: Dry eye disease, Lymphocytes, Inflammation, Ocular surface,  
Ocular therapy
1. Introduction
As a part of the central nervous system (CNS) and as an organ constantly 
exposed to a wide range of environmental stimuli, the eye has finely regulated 
immune-defense mechanisms. The eye can simultaneously respond to invading 
pathogens and tolerate beneficial, resident bacterial communities (ocular micro-
biota) while conducting its vital function, to capture luminous stimuli and transfer 
the signal to the brain so that they can be assimilated, and images are ultimately 
interpreted [1]. This finely tuned ocular function is protected by immune tolerance 
and defense mechanisms that are highly coordinated [2].
Physical barriers such as the blood–brain barrier (BBB) and the blood–retina 
barrier (BRB) prevent infiltration of systemic blood antigens into the eye protecting 
against a potential immune trigger [1]. Innate and adaptive immune cell popula-
tions are strategically positioned both dispersed throughout the ocular tissue and in 
organized follicles along the eye tissues (eye-associated lymphoid tissue (EALT)) [3].  
This actively promotes a tolerogenic microenvironment, which is maintained by 
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specific programs displayed by these immune cells. For example, antigen-presenting 
cells (APCs) express low levels of MHCII and costimulatory molecules (CD80 and 
CD86), and resident T cells show low production of interferon gamma (IFNγ) and 
enhanced transforming growth factor (TGF) β and interleukin 10 (IL-10). An addi-
tional, highly efficient eye component is tear production by the lacrimal gland. Tears 
are complex fluids whose role is to lubricate the ocular surface by binding to the epi-
thelial surface via the inner mucin layer and to cooperate in microbial containment 
(both pathogen and commensals) as tears contain antimicrobial peptides (AMPs) 
such as lysozyme, lipocalin, lactoferrin, and immunoglobulin A (IgA), which inhibit 
microbial adherence [4–6]. Therefore, diverse surveillance pathways collaborate in a 
coordinated fashion to maintain eye homeostasis.
Despite the effort displayed by the above-mentioned tolerance and defense 
mechanisms, the eye faces challenging situations where overwhelming or persistent 
insults may ultimately alter homeostasis resulting in ocular pathologies. Eye disease 
can arise from the complex interaction between host (genetics, immunity, age, 
and sex) and the environment (air pollution, device exposure, and unsupervised 
medication). Multifactorial origins ranging from infectious and inflammatory to 
autoimmune can result in complex, yet unrelated co-morbidities.
1.1 Dry eye disease
Ocular surface inflammatory diseases such as dry eye disease (DED), which is 
currently the most frequent reason for ophthalmologic visits is projected to be an 
increasing eye morbidity due to lifestyle changes such as prolonged device use [7, 
8]. DED is a group of diseases characterized by a strong inflammatory response 
targeting the ocular surface (conjunctiva, cornea, and meibomian and lacrimal 
glands) [7]. The most updated classification subdivides DED into two broad types: 
tear-deficient (aquodeficient) and evaporative DED. In the aquodeficient DED 
subtype, malfunctioning lacrimal glands (LGs) are often diagnosed. Deficiency 
in LG function is strongly associated with an autoimmune response targeting the 
body’s salivary and lacrimal glands (Sjögren’s syndrome) [7]. In evaporative DED, 
a reduced or altered lipidic composition of tear film is thought to be responsible [8]. 
Meibomian gland dysfunction (MGD) can result in decreased lipidic production, 
which is associated with infectious (bacterial and parasite) and non-infectious 
(hormones and duct obstruction) processes [7].
Manifestations compatible with those observed in DED are widely reported 
worldwide, positioning DED as the most common eye disease. DED is the most 
common eye pathology because this disease can emerge as a primary phenotype; 
that is, a local immune response is generated and sustained in the ocular surface 
and draining lymph nodes [9]. DED is also found as a secondary phenotype, where 
both autoinflammatory (e.g., colitis) [10, 11] and autoimmune diseases (Sjögren’s 
syndrome, rheumatoid arthritis, and lupus) present DED symptoms [12–14]. 
The relevant finding that DED onset precedes autoimmune and non-autoimmune 
diseases in several patients is puzzling, and it has attracted interest from researchers 
worldwide, but the pathways remain to be elucidated.
Regardless of the origin, immune cells and their secreted products are the driv-
ing force of DED [9, 15]; therefore, a comprehensive understanding of the immune 
response as an initiator and perpetuating factor in DED is an area of intense 
research. Our immune system is composed of organs, cells, and molecules perform-
ing in a highly coordinated fashion; although finetuned mechanisms of regulation 
exist, pathologies prove that these mechanisms are not always limiting the intensity 
of the immune response. From the many cellular components of the immune 
response participating in DED, lymphocytes constitute one important component, 
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which, when danger signals are detected, can be activated and become a disease-
promoting player rather than homeostasis-maintaining cell type.
1.2 Lymphocyte diversity in the immune response
Lymphocytes are present in blood and lymph vessels and include innate and 
adaptive subtypes. All lymphocytes originate in the bone marrow (organ where all 
blood cells are created) from a common lymphoid precursor (CLP); however, not all 
lymphocytes reach mature status while in the bone marrow. For example, to achieve 
a mature T cell lineage, migration into the thymus is required, so they can complete 
their maturation through a complex process [16].
Classically, innate lymphocytes are represented by natural killer (NK) cells, 
whereas their adaptive counterparts include T and B cells. However, other lym-
phocytic subpopulations also exist in both innate and adaptive subtypes. The main 
difference between innate and adaptive lymphocytes is that the former express 
receptors encoded in the germline with limited diversity, such as toll-like receptors 
(TLRs) and carbohydrate-recognizing receptors (lectins), amongst others [17]. In 
contrast, adaptive lymphocytes express receptors generated by genetic recombina-
tion, which ultimately results in endless diversity. T and B lymphocytes perform 
gene rearrangements to express surface dimeric (two-chain, membrane-bound) 
T cell receptor (TCR) and B cell receptor (BCR), respectively. The TCR structure 
consists of alpha-beta chains, whereas the BCR structure is characterized by 
heavy and light chains forming a membrane-inserted immunoglobulin [18]. Thus, 
conventional innate lymphocytes are the NK cells and the conventional adaptive 
lymphocytes are the T and B cells.
An extended functional and phenotypical characterization of lymphocytes 
recently uncovered a growing diversity in lymphocytic subpopulations. A group 
of lymphocytes bearing low diversity TCRs and simultaneously expressing surface 
markers of NK was identified and named NKT cells [19]. Whereas most T cells 
express TCRs composed of classical alpha-beta chains, a less-abundant, mucosa-
dwelling subtype of T cells express TCRs composed of gamma-delta chains, which 
is referred as γδ T cells [20]. Currently, both NKT and γδ T cells are considered 
unconventional T cells. More recently, other unconventional innate-like lympho-
cytes have been identified and these include the group 2 and group 3 innate lym-
phoid cells (ILC2s and ILC3s, respectively) [21] and mucosal-associated invariant T 
cells (MAITs), whose role has been widely explored in other mucosal surfaces (gut, 
skin, and lungs) [22].
B cells also have an innate-like counterpart; therefore, B cells are also subdivided 
into B1 and B2 cells. B1 cells mostly reside in the peritoneal and pleural cavity and 
produce low-affinity antibodies without stimulation (naturally produced antibod-
ies), whereas B2 cells can produce high-affinity antibodies (affinity maturation 
process) and highly efficient memory responses [23].
Regarding their role within the immune response, all these lymphocytic cells 
contribute to a wide variety of both physiological and pathological processes. 
Lymphocytes residing and circulating during homeostatic conditions participate in 
immune surveillance; however, lymphocytes can be rapidly activated and col-
laborate in pathogen clearance. Furthermore, lymphocytes are involved in highly 
specialized functions such as the generation of memory responses, which allows 
increased intensity and efficiency in a secondary response. Lymphocytes addition-
ally participate in the amplification of the immune response by rapidly releasing 
cytokines and chemokines (helper subpopulations) and preventing pathogen and 
tumor cells dissemination by elimination of infected or transformed cells (cytotoxic 
and killer types). Conversely, specific lymphocytes are also able to down-modulate 
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the intensity of the immune response, thus turning these cells into regulatory 
subtypes, which are central in the resolution phase of the inflammatory process.
As above-mentioned, lymphocytes are active players both as promoters and 
regulators of inflammatory diseases. In the case of DED, how lymphocytes might be 
involved in the immunopathology of this disease was only recently described, and 
the understanding of these lymphocyte-driven pathological pathways may pave the 
way for new therapeutic opportunities.
2. The role of lymphocytes in DED
2.1 NK cells
NK cells are an early source of cytokines, such as interferon (IFN)γ and tumor 
necrosis factor (TNF)α and display cytotoxic features that place them in the first-
line defense against intracellular pathogens and tumor cells. NK cells are grouped 
into the innate arm of the immune response since they lack antigen-specific 
receptors such as those found on adaptive cells (i.e., TCR and BCR) [24]. To fulfill 
their primary cytolytic role, NK cells are equipped with killer-activating receptors 
(KARs) as well as killer-inhibitory receptors (KIRs), whose role is integrating exter-
nal signals that modulate the release of perforin and granzyme-containing granules 
that eliminate target cells. NK cells additionally express pattern-recognition recep-
tors (PRRs), cytokine and chemokine receptors, and antibody Fc fragment recep-
tors, all of which also contribute to NK functions [24].
NK cells were reported to be present in human conjunctiva samples obtained 
by cytology, and DED patients showed similar numbers of NK cells, suggesting 
that NK cell populations are not increased in DED [25]. Moreover, mouse studies 
showed that NK cells are found in the healthy conjunctiva, and DED induction 
caused a rapid infiltration of NK cells into the ocular surface (cornea and conjunc-
tiva) as well as NK cell expansion in the draining cervical lymph node (CLN) [26–28]. 
A dual role for NK cells in the immunopathology of DED has been described. On 
one hand, it was reported that NK cells progressively decrease upon DED induction, 
which was paralleled by lower levels of IL-13 and goblet cell loss [29]. Thus, NK 
cells were identified as an IL-13 source. In turn, IL-13 prevented goblet cell loss, 
assigning a protective role to NK cells during DED (Table 1). Additionally, cyclo-
sporine A (CsA) administration preserved NK cells and down-regulated pathogenic 
IFNγ and IL-17 cytokines [29]. On the other hand, a pathogenic role for NK cells in 
acute mouse DED was suggested since NK depletion with either antibodies (anti 
NK1.1) [26, 28] or antiasialo rabbit serum [27] ameliorated DED signs as gauged 
by less corneal damage (Table 1). Mechanistically, when IFNγ-producing NK 
cells were depleted, a reduced expression of costimulatory molecules (CD80 and 
CD86) in antigen-presenting cells (APCs), such as macrophages and dendritic cells 
(DCs), was found [26]. In line with this, immune neutralization of NK cells reduced 
CXCL9, CXCL10, and CXCL11 chemokines and IFNγ [28]. Furthermore, NK cells 
were identified as a source of the highly pathogenic cytokine IL-17 [27]. Ablation of 
NK cells resulted in matrix metalloproteinase (MMP) 3 and MMP9 attenuation in 
the cornea. Therefore, NK cell depletion strongly impacts pathogenic cytokine and 
chemokine output as well as APC activation, suggesting that rapid NK cell activa-
tion and further cytokine secretion in turn activate APCs to contribute to DED.
Mouse studies suggested that NK cells reside in the ocular surface and, upon 
DED induction, a highly dynamic cytokine response in these cells is initiated. 
However, depending on the cytokine profile released by NK cells, a differential 
impact on the DED outcome is observed. Altogether this mouse evidence suggested 
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Cell type Strain DED type/
model
Role disease Ref









NK cells were identified as an abundant 
source of IL-6, IL-17, IL-23, and IFNγ 
cytokines. NK cell depletion ameliorated 
DED outcome, related to decreased 
MMPs expression in cornea and lower 
costimulatory molecules on APC surface.
A beneficial role was attributed to resident 
NK in maintaining Goblet cells by 
secreting IL-13.
[26, 29, 30]







NKT cells released IL-13, which 
collaborated in preserving goblet cells in 
the ocular surface.
[29]
ILCs N.D. N.D. N.D.






Upon DED induction, γδ T cell numbers 
tend to decrease on conjunctiva, 








Th1 cells were present in draining lymph 
nodes from DED-induced mice and 
contributed to the recruitment of Th17 
cells and inflammatory macrophages 
polarization. Th1 cells secreted IFNγ, 
which in turn induced goblet cell apoptosis 













Conjunctiva and cornea epithelia 
created a Th17 response. Memory Th17 
cells promoted chronic DED. Th17 cells 
induced VEGF, which resulted in ocular 
angiogenesis. Th17 cells were highly 
pathogenic in DED, since they promoted 
MMPs expression and corneal barrier 













Rats induced with autoimmune DED 
showed damaged lacrimal and salivary 
acinar cells, accompanied by a massive 
T cell infiltration, where CD8+ T 
cells dominated over CD4+ T cells. A 
pathogenic role for CD8+ T cells was 
postulated.
Upon acute DED induction, numbers 
of CD8+ T cells were reduced in both 
conjunctival epithelium and stroma, and 
regulatory CD8+ T cells were described 
in DED.
[39–41]







T cell transfer 
mediated-DED
CD4+CD25+Foxp3+ T regs preserved tear 
production and reduced mononuclear 
cell and neutrophil infiltration when 
transferred into nude mice induced with 
Sjögren’s syndrome-like disease. Treg 
cells from DED mice exhibited defective 
suppressive ability rather than decreased 
numbers.
[36, 39]
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a dual role of NK cells in DED; a switch from normal protective IL-13-mediated to 
a pathogenic IFNγ- and IL-17-mediated role has been proposed for the eye-resident 
NK population [27]. What triggers either a protective or pathogenic program in NK 
cells and the role of NK cells in human DED remains to be determined.
2.2 NKT cells
NKT cells are a subgroup of innate-like lymphocytes that recognize lipid anti-
gens presented by MHC class-I-like molecule (CD1d) and are identified by the co-
expression of TCR and the NK-related NK1.1 marker. NKT cells are further divided 
into type I NKT or invariant NKT cells (iNKT) and type II NKT cells. Type I NKT 
cells express a semi-invariant TCR, whereas type II NKT cells possess a more diverse 
TCR repertoire. Upon NKT activation by either lipid antigens or bacterial products 
sensed by TLRs, these cells rapidly secrete large amounts of cytokines, such as IFN-
γ, TNF-α, IL-2, IL-4, IL-5, and IL-13, which modulate the function of neighbouring 
innate and adaptive cells. In organs such as the liver, NKT cells are abundant and the 
main players of the local response; however, in the eye, NKT cells are shown to be a 
relevant cell type [45].
Pioneer studies identified NKT cells as the resident population in the mouse 
ocular surface. Cells isolated through immunobeads from the mouse ocular surface 
under homeostatic conditions were identified using reliable NKT markers (TCR 
and NK1.1). Moreover, these cells were found to be an important source of IL-13; 
through the secretion of this molecule, NKT cells help to preserve the goblet cells, 
which promote ocular surface stability by producing mucins (Table 1) [29]. The 
same group of researchers subsequently confirmed their findings by identifying 
cells positively stained for CD3 and NK1.1 markers, a phenotype compatible with 
NKT cells in conjunctiva samples from healthy mice [30]. Interestingly, these 
authors reported that the actual number of NKT cells was higher than the number 
of conventional T cells (CD4 and CD8 lymphocytes), suggesting that, like in other 
epithelial tissues, NKT cells are abundant in the ocular surface [30].
Therefore, the evidence, although minimal but convincing, shows that NKT cells 
are fundamental for maintenance of the ocular surface through communication 
with goblet cells. Impaired crosstalk between these cells adds to the development of 
DED, so a protective role can therefore be inferred for NKT cells in DED.
2.3 γδ T cells
T lymphocytes bearing a TCR composed of gamma-delta chains (γδ T cells) are 
less abundant than αβ T cells; however, γδ T cells represent a major T cell popula-
tion in the epithelial tissues such as the skin, and gastrointestinal and reproductive 
Cell type Strain DED type/
model
Role disease Ref





Plasma cells release IgG antibodies 
targeting components from the lacrimal 
gland (Kallikrein 13). When purified, 
these anti-kallikrein 13 antibodies induced 
DED signs. B cells could be activated more 
efficiently by IL-17 than by IFNγ. B cells 




The diverse roles of lymphocytes in rodent DED.
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tracts. As part of the intraepithelial lymphocytes (IELs), γδ T cells are central 
players in the protection and homeostasis of surfaces in constant contact with the 
external environment. Specifically in the eye, γδ T cells collaborate in maintaining 
ocular immune privilege [46].
Early evidence arose from studies on the non-diabetic obese (NOD) mouse 
strain, which, upon ageing, develop a Sjögren’s-syndrome-like disease. When DED 
was induced in NOD mice via scopolamine delivery, symptoms such as a decreased 
tear volume and goblet cell density as well as increased corneal permeability were 
observed (Table 1). The authors noted a significant decline in the numbers of γδ T 
cells in the conjunctival epithelium during the acute phase of DED [31]. Intriguingly, 
using the same DED model (scopolamine administration) in a different mouse strain 
(C57BL/6), decreased numbers of γδ T cells present in the conjunctival epithelium 
were observed when DED was induced, but increased γδ T cells were visible in flow 
cytometry samples [30]. Moreover, a strain-dependent effect of γδ T cells on tear 
volume was found where C57Bl/10 J (B10) mice lacking γδ T cells presented higher 
tear volume compared with C57BL/6 J (B6) similarly lacking γδ T cells [47].
Regarding human DED, the role of γδ T cells has not yet been explored; how-
ever, Sjögren’s syndrome patients are reported to present altered numbers of γδ T 
cells. One may speculate that as DED is frequently observed in Sjögren’s syndrome 
patients, in human DED secondary to autoimmune disease, a modified γδ T cell 
response is expected.
Salient evidence suggests that the depletion of γδ T cells is a hallmark of experi-
mental DED, supporting an immunoregulatory role of the γδ T cells despite them 
being a well-known source of pathogenic IL-17 (Table 1). This regulatory role is 
further supported by mice lacking γδ T cells not developing anterior-chamber-asso-
ciated immune deviation (ACAID), and corneal grafts are more tolerated when γδ 
T cells are present [48]. An anti-inflammatory role for γδ T cells in DED is currently 
accepted.
2.4 T helper cells
T cells and B cells compose the lymphocytes of the adaptive immune system. 
T cells are further subdivided into T helper (Th) and T cytotoxic (Tc) groups, 
identified as CD4+ and CD8+, respectively. CD4+ Th cells are abundant lymphocytes 
with the primary role of secreting cytokines to amplify the immune response by 
promoting crosstalk amongst cells. Once activated, Th cells proliferate and polarize, 
which means they selectively secrete specific groups of cytokines and chemokines. 
Currently, effector Th cells are grouped based on the cytokines released as follows: 
Th1 cells secrete IFNγ; Th2 cells secrete IL-4, IL-5, and IL-13; Th17 cells secrete 
IL-17; and Th22 cells secrete IL-22. Compared with effector Th cells, regulatory Th 
cells produce IL-10 and are termed type 1 T regulatory cells (Tr1). As Th cells have 
been shown to be highly pathogenic and contribute to inflammatory disease, specif-
ically Th1 and Th17 cells, these subpopulations are under intense research in DED.
CD4+ and CD8+ T cells are less abundant on the healthy ocular surface com-
pared to γδ T cells and it has been noted that CD4+ T cells outnumber CD8+ T cells. 
Induction of DED in rodents and in patient with DED, T cells are found to consis-
tently infiltrate the ocular surface. In early mouse studies of DED, upon desiccant-
stress-induced DED, increasing numbers of CD4+ T cells were observed in the 
cornea, conjunctiva, and lacrimal gland tissues [39] (Table 1). It was demonstrated 
that transferring these cells is enough to induce DED in mice lacking T and B cells, 
showing that CD4+ T cells are largely responsible for inducing DED (Table 1) [39]. 
Additional reports also provided evidence of CD4+ T cells driving autoimmune 
DED in autoimmune regulator-knockout (Aire KO) mice [49] and being present in 
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lacrimal glands in a novel autoimmune model of DED in rats [40]. This same popu-
lation was found to be expanded within draining lymph nodes from DED-induced 
mice [32]. Similarly, human studies showed that DED patients with an autoimmune 
origin (Sjögren’s syndrome) and with a non-autoimmune origin (non-Sjögren) 
presented comparable numbers of CD4+ T cells assessed per immunohistochemistry 
using conjunctival samples [50].
Research has also focused on identifying specific subtypes of CD4+ T cells 
involved in DED, where Th1 and Th17 cells have received the most attention 
since DED induction was found to cause increased transcripts of both IFNγ and 
IL-17 in the ocular surface [34]. Expansion of IFNγ-secreting CD4+ T cells co-
expressing CXCR3 and CCR5 chemokine receptors (Th1 polarized T cells) in the 
regional lymph nodes (submandibular and cervical) has been reported [32, 51]. 
Interestingly, IFNγ may be highly relevant at the onset of DED, but its role during 
chronic DED may be limited [49]. The relevance of Th1 in DED immunopathology 
can be inferred due to the detrimental effect of IFNγ on the ocular surface, since 
the presence of IFNγ receptor was demonstrated on the conjunctival and corneal 
epithelium [33]. Additionally, IFNγ is amongst the cytokines elevated in tears from 
DED patients and was shown to alter mucin secretion by inducing cell death in 
conjunctiva-residing goblet cells [52]. A diminished density of goblet cells resulting 
from IFNγ administration was also reported [41]. IFNγ was also found to be respon-
sible for inducing apoptosis in lacrimal gland cells [53].
Once polarized and activated, Th2 cells secrete IL-4, IL-5, and IL-13 cytokines. 
Even though DED is a Th1-prone inflammatory condition, it has been reported that 
tear samples from DED patients contain elevated levels of IL-4, IL-5, and IL-13, 
suggesting activation of the Th2 pathway [54–56]. Intriguingly, Th2 cytokines were 
detected elevated in tears from DED-induced experimental animals [57]; however, 
the contribution of the cytokines to mouse DED appears to be strain-dependent, 
since DED induction caused different cytokine and chemokine profiles in C57BL/6 
compared with BALB/c mice [58]. Although IL-13 has been shown to prevent goblet 
cell loss, innate lymphocytes (NK and NKT cells) were demonstrated to be the cel-
lular source; thus, we can speculate that Th2 cells collaborate in preserving mucin-
producing cells as well. However, this remains to be proven.
In terms of Th17 cells, DED induction creates a Th17-inducing microenviron-
ment as gauged by a rapid increase in IL-6 and IL-23 expression. Th17 cells have 
been readily detected in draining lymph nodes from acute and chronic DED-
induced mice [34, 35], and their pathogenic role is supported by experimental evi-
dence showing that IL-17 neutralization attenuated corneal damage. Furthermore, 
Th17 cells emerging in experimental DED were shown to be resistant to suppres-
sion exerted by T regulatory cells and, unlike Th1 cells, Th17 cells survived longer 
periods of time, adding to chronic DED [36]. A wide variety of negative effects on 
the ocular surface have been attributed to Th17 cells and IL-17 including promotion 
of MMPs expression, corneal barrier damage, and induction of angiogenesis via 
vascular endothelial growth factor (VEGF) (Table 1) [37].
Another group of CD4+ T cells addressed in the context of DED is the T regula-
tory (Treg) subtype. Treg cells are identified by the expression of the transcription 
factor Foxp3 and high levels of CD25 and can suppress cell proliferation. Niederkorn 
et al. demonstrated that the presence of Foxp3+ Tregs prevented DED symptoms 
induced by the adoptive transfer of ocular-surface-specific T effector cells (Table 1)  
[39]. Thereafter, it was shown that a percentage of lymph node residing Foxp3+ 
Tregs remains unaltered upon DED induction but their suppressive ability is reduced 
compared with their counterparts from non-DED animals, when tested in vitro [36]. 
Recently, administration of histone deacetylase inhibitors (HDACi)-containing 
microspheres that stabilized Foxp3+ expression reduced DED signs [59].
9
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Several CD4+ T subtypes have been identified in DED, and the roles of Th1, 
Th17 and Tregs have been highlighted. A well-established pathogenic role of Th1 
and Th17 in inducing ocular surface damage through the release of IFNγ and IL-17, 
respectively, has been assigned. In sharp contrast, Treg cells are responsible for 
restraining exacerbated inflammatory responses in the ocular surface. Therefore, 
the balance between these CD4+ T cells subpopulations seems to be determinant for 
the onset and chronicity of DED.
2.5 T cytotoxic cells
Although T cytotoxic cells (CD8+ T cells) also contribute by producing cytokines 
such as IFNγ, they are best known for their cytolytic functions. CD8+ T cells contain 
granules with perforin and granzyme, which are delivered to the target cells with 
the goal of inducing cell death via membrane damage and cellular content release. 
A few studies have addressed the role of CD8+ T cells in DED, and the evidence 
is controversial. It was suggested that CD8+ T cells might play a regulatory role, 
since a significant loss of CD8+ T cells in the conjunctiva was found to accompany 
the development of DED [30] and DED patients showed increased CD4/CD8 
compared with healthy donors (Table 2) [25]. Furthermore, thrombospondin 1 
(TSP1)-deficient mice exhibited DED symptoms accompanied by dramatic lacrimal 
gland cell infiltration, where CD4+ T cells were significantly increased; CD8+ T cells 
were not increased compared with those in mice expressing TSP1 [65]. Conversely, 
CD8+ T cells were the dominant cell type in severely damaged ducts within lacrimal 
glands of rats induced with an autoimmune DED model [40]. In line with this, 
Cell type DED type Role in Disease Ref
NK cells Non SS A putative limited role was assumed since NK numbers 
were not different between healthy controls and DED 
patients
[25]
NKT cells N.D. N.D.
ILCs N.D. N.D.
γδ T cells N.D. N.D.
T helper 
cells
SS and Non SS Highly infiltrated in lacrimal glands from SS patients. 
Increase in CD4+ T cells numbers correlated with 
dryness, hyperemia, and itching score. Th cells 
secreted IL-21, which in turn favors B cell transition 
to plasma cells. Different T cell subpopulations were 
associated with differential DED signs, for instance, 
CD4+CCR7+CD45RO−CD45RA+ correlated with 
hyperemia, whereas patients with CD4+CCR7−CD45RO
+CD45RA−CD69−CD103− cells showed reduced tear film 
break up time (BUT). Memory T cells (CD4+CD45RA−) 





SS and Non SS The presence of Tc cells with the phenotype 
CD8+CCR7+CD45RO−CD45RA+ positively correlated 
with hyperemia. Conversely, CD8+CCR7−CD45RO and 
CD45RA+CD69+CD103+ were abundant when patients 
largely exhibited reduced tear film
[63]
B cells SS untreated Produced antinuclear antibody (ANA) [62]
SS; Sjögren’s Syndrome, N.D.; not documented.
Table 2. 
The role of lymphocytes in human DED.
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using a mouse autoimmune model of Sjögren’s syndrome, lacrimal glands pre-
sented a massive infiltration of CD8+ T cells [53], and aged mice displaying ocular 
surface pathology (corneal irregularity and conjunctival goblet cell loss) presented 
increased numbers of CD8+ T cells [42].
Therefore, additional studies are needed to better understand the role of CD8+ T 
cells during DED development. In the current literature, most of the mouse studies 
investigate immunological changes during the acute stage of disease; however, it 
is well-known that DED is a chronic disease. Thus, the role of resident cells might 
contribute to the infiltration of additional pathogenic populations responsible for 
perpetuating the inflammatory process. A differential role of CD8+ T cells occurring 
during early versus late stages of disease cannot be ruled out.
2.6 B cells
B lymphocytes complement T cells in adaptive immunity and in generating 
immune memory responses. B cells perform a variety of functions in homeostatic 
conditions and following the initiation of an adaptive immune response. These 
functions include cytokine release, antigen processing and presentation, and their 
signature role as antibody-producing cells. In mucosal surface immunosurveillance, 
the presence of IgA is pivotal in limiting pathogen invasion. In the EALT, B cells are 
present in both diffuse and organized (follicles) forms to support their function. B 
cells are essential in eye-associated immune responses ranging from surveillance to 
autoimmune-mediated diseases and allergies.
As mentioned above, human DED can arise from autoimmune diseases 
(Sjögren’s syndrome and rheumatic) and DED was proposed to be a mucosal auto-
immune disease [66]. Despite being proposed as an autoimmune disease, the role of 
B cells in both human and mouse DED has not been completely addressed.
In terms of studies in patients with Sjögren’s syndrome, autoimmune-response-
targeting exocrine glands (salivary and lacrimal) are the driving force of the 
disease; however, human studies mostly focused on the salivary glands rather than 
lacrimal glands and the ocular surface. Information learned from patients with 
Sjögren’s syndrome linking B cell subpopulations and eye manifestations is still 
lacking. More thorough research on B cells and their participation during mouse 
DED must be conducted.
Thus far, the role of B cells in mouse models of DED may be model-dependent. 
When DED was induced via pharmacological inhibition of the lacrimal gland func-
tion (desiccant stress), no significant changes were observed regarding the percent-
age of B cells present in the tissue (Table 1) [30]. Likewise, the NOD autoimmune 
model of DED was attenuated by blocking high-mobility group box 1 (HMGB1) with 
neutralizing antibodies; however, no substantial changes in either the percent of B 
cells or in IL-10-producing B cells were found [67]. Conversely, when DED symptoms 
were evaluated in aged mice, without any additional chemical agent, B cell numbers 
were found to be increased accompanying DED development [42]. A pathogenic role 
of B cells in DED is supported by the findings showing that a DED-like disease can be 
generated by transferring antibody-containing serum (purified IgG isotype) obtained 
from mice previously induced with DED for three weeks [43]. The transfer of anti-
bodies required the presence of complement proteins to cause ocular surface damage 
[43], suggesting that in eye tissue exposed to desiccant stress, antibodies targeting 
lacrimal gland components like kallikerin 13 are induced (Table 1). Additionally, 
IL-17 collaborates in B cell proliferation and plasma cells generation [44].
Recent findings show that B cells are instrumental in DED, either human or 
mouse; however, the only mechanism through which these B cells induce eye 
damage is proposed to be by secreting antibodies targeting lacrimal gland antigens. 
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To prove that additional pathways are also regulated by B cells resulting in Sjögren-
associated and non-Sjögren-related DED, future studies are required.
3. The future players in DED
Both novel techniques (single cell sequencing and massive flow cytometry) 
and the discovery of novel functions have allowed the better characterization of 
immune cell populations, revealing a wider diversity of lymphocyte subpopula-
tions than previously thought. As an example, mucosal-residing ILCs have emerged 
as central early regulators in the immune response. In the case of inflammatory 
diseases, including DED, lymphocyte populations have specifically received more 
attention than others, which does not imply that the populations that we do not 
yet understand are less important. Notably, MAITs and ILCs are only beginning to 
arise as potential drivers in eye pathologies. Few studies have, for instance, shown 
that extremely low numbers of ILC2s reside in the mouse cornea and are recruited 
upon corneal epithelial injury, where they are required for cornea tissue repair 
[68]. Additional studies described that cells, presumably ILCs, can be isolated from 
human and mouse conjunctiva [69]. In eye pathologies, MAITs were reported to be 
increased in acute anterior uveitis [70] and ILCs played no role in ocular infection 
with herpes simplex virus (HSV)2 [71]. Thus, a role for MAITs and ILCs cannot 
be ruled out in DED, and future evidence will further our understanding of the 
expanding universe of lymphocytes in DED.
4. Targeting lymphocytes as therapy for DED
The findings summarized here strongly indicate that resident lymphocytes can 
rapidly be activated when the microenvironment in the ocular surface is altered 
by the lack of tears (aquodeficient) or have altered composition (evaporative). 
Evidence now suggests that innate and adaptive lymphocytes regulate the onset and 
persistence of DED. For instance, NK are shown to switch their cytokine response, 
which is critical for initiating DED, whereas other innate lymphocytes such as γδ T 
cells and NKT cells are mostly suppressive in homeostasis, and DED may parallel 
the loss of these populations. Regarding the adaptive lymphocytes, T and B popula-
tions are responsible for promoting chronicity. The important role of lymphocytes 
during DED is also supported using diverse therapeutics aimed to attenuate lym-
phocyte activation; thus, controlling lymphocyte populations has long been con-
sidered an efficient therapy for DED. These strategies include diverse methods of 
controlling T cells response; for instance, cyclosporine A (CsA) eyedrops targeted 
cell proliferation [72, 73]. It has been reported that commercially available CsA for-
mulations such as Restasis (0.05% CsA, Allergan) and Ikervis (0.1% CsA, Santen) 
are highly effective in treating DED, however, side effects which are thought to be 
vehicle-related, have been reported [74, 75]. Therefore, improving CsA delivery 
is the current challenge. Recently, results from phase II and phase III clinical trials 
have been released. Wirta et al. published their results from a USA-centered phase II 
trial (efficacy, safety and tolerability) using a water- and oil-free emulsion contain-
ing a 0.1% CsA dose termed CyclASol for 16 weeks that resulted in earlier and more 
effective relief in adult DED patients compared to Restasis (Allergan) administered 
under the same protocol [76]. In an independent study, CsA was encapsulated in 
nanomicelles to enhance its effectiveness. The authors hypothesized that given the 
hydrophobic nature of CsA that dampens aqueous solubility encapsulating CsA  
in nanomicelles would help to solubilize CsA and ultimately increase its efficacy. 
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The 0.09% CsA nanomicellar solution, termed OTX-101, was administered for 
84 days in individuals (18–90 years old) and significantly increased integrity of the 
ocular surface [77]. Thus, CsA still remains as one of the most recommended DED 
therapies and these efforts to enhance its effects by using novel ways of delivery 
with promising results keep expectations high to achieve complete DED remission.
Additional DED therapies targeting lymphocytes include eyedrops containing 
anti-CD4 antibodies suppressing cell activation [78] and more recently, blocking T 
cell infiltration by antagonizing LFA1 (Lifitegrast) [79]. Therapies increasing regu-
latory lymphocytes are another method of ameliorating DED. Rebamipide, which 
promotes the expansion of regulatory adaptive lymphocytes, yielded promising 
results in autoimmune DED [80]. More sophisticated agents such as histone deacet-
ylase inhibitor (HDACi)-containing microspheres aimed at stabilizing regulatory T 
cells have also shown beneficial effects on DED symptoms [59].
Thus, currently approved drugs as well as experimental evidence (NK depletion) 
show that regulating both innate and adaptive lymphocytes can be a complimentary 
therapy for strategies to restore healthy tears. The more we understand about how 
lymphocytes participate in DED, the greater the possibilities of mitigating DED.
5. Conclusion
There has been a tremendous breakthrough concerning DED research, from 
previously being considered only as a syndrome to what is now recognized as the 
most common eye pathology. Experimental models have been instrumental for the 
better understanding of DED immunopathology; unfortunately, human studies 
are underrepresented. Convincing evidence obtained mostly from animal studies 
shows that lymphocytes have important implications in DED, placing Th1, Th17, 
and B cells as the main pathological subtypes, which seem to be in constant compe-
tition with immune cell populations mostly displaying regulatory features such as 
Tregs that are ultimately responsible for lessening the intensity of disease-promot-
ing counterparts. Contrary to the extensive work that has been done describing how 
adaptive cells are active players in both promoting and regulating DED, evidence is 
just starting to uncover surprising roles attributed to innate and innate-like lym-
phocytes. As we have reviewed here, strong evidence, up to now, suggests possible 
“program switching” in resident innate cell populations like NKs whereas other cells 
such as NKT and T cells rather display a regulatory role contributing to a tolerogenic 
microenvironment on the ocular surface. More recently, cell populations like ILCs 
have been described expanding upon eye tissues injury, which paves the way to 
uncover novel roles for these ILCs in a variety of eye pathologies, similarly to other 
organs. Continued research will help to clarify how these populations contribute to 
DED immunopathology. It is evident that additional human studies would comple-
ment and validate these findings, with the ultimate goal of identifying new thera-
peutic targets based on modulating lymphocyte responses. We have also shown that 
some of the most effective DED treatments indeed target lymphocyte populations 
(cyclosporine A and LFA-1 inhibitors) and current trials are aimed to develop a 
more efficacious way to deliver these drugs with proved benefit in DED therapy.
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